Taskforce

COVID-19 - Clinical Guidance Task Force

ASAM Clinical Guidance Task Force

COVID-19 was declared a world pandemic on March 11.  Patients with addiction are a vulnerable population with unique challenges in light of COVID-19.  Many patients with addiction have other co-occurring conditions and depending on the severity of their disease and access to economic and social support, such individuals may cycle in and out of emergency departments, addiction treatment centers, homeless shelters and other facilities.  These circumstances pose unique challenges regarding COVID-19 transmission and the severity of the illness if contracted by patients with SUD. At the very least proper attention to infectious disease issues will decrease the infection rate among this population and their families.

This Task Force is charged to develop guidance resources for clinicians to use as they sort out how to handle the impact of COVID-19 on their practice and in the treatment of patients with addiction.

As of: 3/25/20

Task Force Members

Yngvild Olsen, MD, MPH, DFASAM Chair

Kelly Clark, MD, MBA, DFAPA, DFASAM Vice Chair

Alexis Polles, MD

Brad Hall, MD, DABAM, DFASAM

Cara Poland, MD, MEd, DFASAM

Chinazo Cunningham, MD, MS, FASAM

Chris Bundy, MD, MPH, FASAM

David Goodman, MD

Jessie Schaumburg, MD

Kinna Thakarar, MD, DO, MPH, FASAM

Lewis Nelson, MD, FASAM

Margaret Jarvis , MD, DFASAM

Mishka Terplan, MD, MPH, FACOG, DFASAM

Nishant Shah, MD

Paul Trowbridge, MD

Sarah Kawasaki, MD, FASAM

Scott Hambleton, MD, DFASAM

Shawn Ryan, MD, MBA, FASAM

 

Content Reviewers

Paul Earley, MD, DFASAM ASAM President

Yngvild Olsen, MD, MPH, DFASAM Chair

Kelly Clark, MD, MBA, DFAPA, DFASAM Vice Chair

Margaret Jarvis, MD, DFASAM

Ken Freedman, MD, MS, MBA, FACP, AGAF, DFASAM

ASAM Staff

Maureen Boyle, PhD

Kelly Corredor, JD 

Anna Garbar

Penny Mills, MBA

Zach Semple